The highest-ranked TipRanks' corporate insider is an unknown 80-year-old investor in Birmingham, Alabama, who advises and sits on multiple boards. His track record has made him a legend on the platform: Out of the 496 trades he's made since 2014 in Alabama's ServisFirst Bancshares Inc., where he sits on the board, and Century Bancorp Inc. of Massachusetts, where he owns more than 10% of the stock, 372 of them or about three quarters have been winning trades three months later. When Filler makes a trade, his Form 4 is released two days after and automatically updated on TipRanks. He's got about 2,700 subscribers on the platform that are alerted after he makes a trade.
Besides Filler, other TipRanks favorites include Steve Mihaylo, the CEO of telephone services company Crexendo Inc., who has a win rate of 83% over the last five years; Snehal Patel, CEO of pharmaceutical company Greenwich LifeSciences Inc., who has earned 488% on four trades that were made ahead of results from a cancer drug trial.
Many insiders' high success win rates seem as if it's just luck, but it's been an open secret on Wall Street that insiders trade on what they know. Wharton's Taylor said, "there is a lack of appreciation for the amount of opportunistic abuse that exists under the current system, the amount of egregiousness."
Last year, readers may recall pharmaceutical execs adopted so-called 10b5-1 plans - trading schedules that are preplanned buying and selling programs over time. However, many of the preplanned trades were based on COVID vaccine announcements. In particular, Pfizer CEO Albert Bourla, who, under the 10b5-1, dumped shares on a vaccine announcement.
https://www.zerohedge.com/markets/pfizers-ceo-dumps-60-his-stock-covid-vaccine-announcement 
